Our above findings revealed a close association between Tregs and tumor cells concerning the prognosis of NSCLC patients and current research unveiled the interaction of PD-1/PD-L1 influencing the proliferation and function of FOXP3+ Treg cells [22–25], which could offer novel insights to enhance the efficacy of anti-PD-1/PD-L1 antibody treatments. The gene discussed is FOXP3; the disease is neoplasm.